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Alterations in density and morphology of the cerebral microvasculature have been
reported to occur in Alzheimer’s disease patients and animal models of the disease.
In this study we compared magnetic resonance imaging (MRI) techniques for their utility
to detect age-dependent changes of the cerebral vasculature in the arcAβ mouse model
of cerebral amyloidosis. Dynamic susceptibility contrast (DSC)-MRI was performed by
tracking the passage of a superparamagnetic iron oxide nanoparticle in the brain with
dynamic gradient echo planar imaging (EPI). From this measurements relative cerebral
blood volume [rCBV(DSC)] and relative cerebral blood flow (rCBF) were estimated. For
the same animal maps of the relaxation shift index Q were computed from high resolution
gradient echo and spin echo data that were acquired before and after superparamagnetic
iron oxide (SPIO) nanoparticle injection. Q-values were used to derive estimates of
microvessel density. The change in the relaxation rates 1R∗ obtained from pre- and2
post-contrast gradient echo data was used for the alternative determination of rCBV
[rCBV(1R∗ )]. Linear mixed effects modeling found no significant association between2
rCBV(DSC), rCBV(1R∗ ), rCBF, and Q with genotype in 13-month old mice [compared to2
age-matched non-transgenic littermates (NTLs)] for any of the evaluated brain regions. In
24-month oldmice there was a significant association for rCBV(DSC) with genotype in the
cerebral cortex, and for rCBV(1R∗ ) in the cerebral cortex and cerebellum. For rCBF there2
was a significant association in the cerebellum but not in other brain regions. Q-values in
the olfactory bulb, cerebral cortex, striatum, hippocampus, and cerebellum in 24-month
old mice were significantly associated with genotype. In those regions Q-values were
reduced between 11 and 26% in arcAβ mice compared to age-matched NTLs. Vessel
staining with CD31 immunohistochemistry confirmed a reduction of microvessel density
in the old arcAβ mice. We further demonstrated a region-specific association between
parenchymal and vascular deposition of β-amyloid and decreased vascular density,
without a correlation with the amount of Aβ deposition. We found that Q mapping was
more suitable than the hemodynamic read-outs to detect amyloid-related degeneration
of the cerebral microvasculature.
Keywords: Alzheimer’s disease, microvessel density, dynamic susceptibilty contrast MRI, relaxation rate shift
index, superparamagnetic iron oxide nanoparticles, cerebral amyloidosis, cerebral amyloid angiopathy
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder and the most common form of dementia (Lopez, 2011;
Mangialasche et al., 2012). AD pathology is characterized by
changes in β-amyloid (Aβ) metabolism, abundance of soluble
Aβ oligomers, parenchymal Aβ deposits and neurofibrillary
tangles, synaptic dysfunction and neurodegeneration, and loss
of cognitive function (Haass and Selkoe, 2007). The pathology
is not restricted to the neuronal compartment as it also affects
all cell types of the neurovascular unit including circulating
leukocytes, endothelial cells, pericytes, perivascular antigen-
presenting cells, astrocytes, and microglia (Iadecola, 2004;
Grammas, 2011; Zlokovic, 2011). A particular attention has been
paid to the vascular system where a number of studies have
provided evidence for pronounced cerebrovascular dysfunction
in AD.
Cerebral hypoperfusion is an early sign of cerebrovascular
dysfunction in AD patients (Hirao et al., 2005; Johnson
et al., 2005). Postmortem histological studies have revealed that
microvessel density is altered in the AD brain. While some
studies reported a reduction in certain brain areas in AD patients
(Bell and Ball, 1986; Fischer et al., 1990; Buèe et al., 1997; Bouras
et al., 2006), other studies have demonstrated hypervascularity
(Desai et al., 2009; Biron et al., 2011). In addition, blood vessels
are morphologically abnormal i.e., they become fragmented,
twisted, or tortuous with glomerular loop formation (Buèe
et al., 1997; Bouras et al., 2006), have an altered vessel wall
composition (Scheibel et al., 1987), and impaired structural
integrity (Farrall and Wardlaw, 2009). It has been hypothesized
that these microvascular distortions can compromise neuronal
function and might thus contribute significantly to the cognitive
decline in AD (de la Torre, 1994; Ostergaard et al., 2013).
Moreover, cerebral amyloid angiopathy that is present in up to
90% of AD patients, involves the deposition of Aβ within the
leptomeninges and parenchymal microvessels (Vinters, 1987).
Cerebral amyloid angiopathy induces degeneration of smooth
muscle cells, impairment of blood-brain barrier function, and the
occurrence of cerebral microbleeds, all of which can compromise
cognitive function (Cordonnier and van der Flier, 2011).
To date, a variety of transgenic animals that mimic
pathological features of AD have been engineered. Among them,
transgenic mice overexpressing the mutant amyloid precursor
protein (APP) are widely used to model Aβ-related pathologies.
APP mice have increased levels of Aβ oligomers, age-dependent
deposition of diffuse and fibrillar parenchymal plaques with
variable degrees of vascular amyloid formation, deficits in brain
metabolism and cognitive function similar to AD patients
(Sturchler-Pierrat et al., 1997; Knobloch et al., 2007; Merlini
et al., 2011; Kulic et al., 2012). Hypoperfusion and aberrations in
microvessel density and morphology have been equally observed
in APPmice (Lee et al., 2005;Miao et al., 2005; Kouznetsova et al.,
2006; Meyer et al., 2008; Biron et al., 2011; Klohs et al., 2012).
Magnetic resonance imaging (MRI) can be used to non-
invasively assess the cerebral vasculature and its function in AD,
and has been widely applied to assess vascular dysfunction in
APP models (for a recent review see Klohs et al., 2014). For
example, magnetic resonance angiography techniques have been
used to reveal abnormalities in vessel morphology and density
in a variety of APP mouse strains (Beckmann et al., 2003; Thal
et al., 2009; El Tayara Nel et al., 2010; Kara et al., 2012; Klohs
et al., 2012). Functional MRI techniques have demonstrated a
reduction of relative CBV (rCBV), cerebral blood flow (rCBF),
and functional connectivity (Wu et al., 2004a; Weidensteiner
et al., 2009; Massaad et al., 2010; Faure et al., 2011; Poisnel et al.,
2012; Hébert et al., 2013; Zerbi et al., 2013; Grandjean et al., 2014).
Moreover, blood-brain barrier impairment and occurrence of
cerebral microbleeds were observed with MRI (Beckmann et al.,
2011; Klohs et al., 2011, 2013, 2015). The application of these
techniques to APP mice is not only useful for the phenotyping
of these mouse strains, but combined with histology also enables
validation of possibly clinical imaging read-outs.
In this study we aimed to assess age-dependent changes in
vascular function in arcAβ mice with different vascular MRI
parameters in vivo.We intended to compare hemodynamic read-
outs related to the overall vasculature such as rCBV and rCBF
and to compare those to the relaxation shift index Q, a measure
of the microvessel density in the same animal. The arcAβ is
an APP overexpressing mouse strain with pronounced vascular
deficits and cerebral amyloid angiopathy (Merlini et al., 2011).
Dynamic susceptibility contrast (DSC)-MRI measurements were
performed by tracking the passage of the SPIO bolus in the brain
with dynamic gradient echo (GE) echo planar imaging (EPI) to
estimate rCBV(DSC) and rCBF in the same animal (Østergaard,
2005). For Q mapping the change in relaxation rates 1R2 and
1R∗2 were estimated from GE and spin echo (SE) data before
and after the injection of superparamagnetic iron oxide (SPIO)
nanoparticle injection when the particle concentration reached
steady-state (Jensen and Chandra, 2000; Wu et al., 2004b). The
change in the relaxation rates 1R∗2 from pre- and post-contrast
GE data was used to determine rCBV(1R∗2), for comparison with
DSC-MRI. Hemodynamic read-outs and Qmaps were compared
with immunohistochemical evaluation of microvessel density
and Aβ deposition.
MATERIALS AND METHODS
Animals
All experimental procedures conformed to the national
guidelines of the Swiss Federal Act on Animal Protection and
were approved by an official committee (license 194/2011,
Cantonal Veterinary Office, Zurich, Switzerland). Male and
female transgenic arcAβ mice overexpressing the human
APP695 with the Swedish and the Arctic (E693G) mutations
(Knobloch et al., 2007) that were backcrossed on a C57Bl/6
background for more than 15 generations and non-transgenic
littermates (NTLs) of the same background were used for the
study. Batches of animals of 13 ± 1 months of age (arcAβ n = 8;
NTLs n = 8) and 24 ± 1 month of age (arcAβ mice n = 8;
NTLs n = 14) were investigated. Animals were housed in a
temperature controlled room in individually ventilated cages,
containing up to five animals per cage, under a 12 h dark/light
cycle. Food and water were provided ad libitum.
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Animal Preparation
Anesthesia was induced using 3% isoflurane (Abbott,
Cham, Switzerland) in a 4:1 air/oxygen mixture. Mice were
endotracheally intubated and mechanically ventilated during
measurements with 80 breaths/minute while applying a
respiration cycle of 25% inhalation and 75% exhalation (MRI-
1Volume Ventilator, CWI Inc., Ardmore, USA) using 1.5%
isoflurane. The tail vein was cannulated for administration
of contrast agents. Body temperature was monitored with a
rectal temperature probe (MLT415, ADInstruments) and kept
at 36.0 ± 0.5◦C using a warm-water circuit integrated into the
animal support (Bruker BioSpin).
Physiological Monitoring
In a subset of 24-months old animals (n = 4) that did
not undergo MRI examination the left femoral artery was
cannulated to monitor mean arterial blood pressure (MABP)
continuously (Transducer and Transbridge Amplifier; World
Precision Instruments, Sarasota, USA) and to provide serial
measurements of arterial blood gases (Compact 2 AVL, Bad
Homburg, Germany).
Magnetic Resonance Imaging
Data were acquired on a Bruker BioSpec 94/30 (Bruker BioSpin
GmbH) small animal MR system operating at 9.4 T. The system
was equipped with a cryogenic 2 × 2 phased-array cryogenic
mouse head surface coil (Bruker BioSpin AG, Fällanden,
Switzerland).
T2-weighted anatomical reference images were acquired using
a SE sequence [Rapid Acquisition with Rapid Enhancement
(RARE)], with an echo time (TE) = 47ms, echo spacing =
11.8ms, repetition time (TR) = 4200ms, RARE factor = 8.
Fifteen sagittal slices of 0.5mm thickness with a field-of-view =
20 × 20mm, and a matrix of 384 × 384 were recorded to give
a nominal resolution of 52 × 52µm. In addition, twelve axial
images of 0.5mm thickness were acquired using the balanced
Steady-State Free Precession type (TrueFISP) sequence. The
imaging parameters were TE = 2.4ms, TR = 4.8ms, flip angel
α = 60◦, excitation pulse length: 1ms; pixel bandwidth: 586ms.
Data were recorded with a field-of-view = 23.7 × 14mm and
matrix of 256 × 256 yielding an in-plane voxel dimension of
92× 55µm.
For Q mapping, global 1st order shimming followed by
fieldmap-based local shimming was performed to reduce static
magnetic field inhomogeneities. Relaxation rates 1R2and 1R
∗
2
were acquired before and after SPIO injection using a SE and GE
sequence, respectively. 2D SE images were acquired with TE =
30ms, TR= 2000ms, RARE factor = 8, in coronal direction, with
6 averages. Three slices of 0.6mm thickness and a 0.6mm slice
gap were acquired with a field-of-view = 19.2 × 19.2mm, and a
matrix of 192×192 to give a nominal resolution of 100×100µm.
The 3DGE sequences (FLASH) were applied with the parameters
TE/TR= 5.5/40ms, α = 5◦, bandwidth of 50 kHz and eight
averages. A slab with field-of-view = 19.2 × 19.2 × 4mm, and a
matrix of 192×192× 40 was recorded to give a spatial resolution
of 100× 100× 100µm. The three SE images were aligned within
the field-of-view of the GE image.
Between pre- and postcontrast images, DSC-MRI data was
acquired with GE EPI with TE = 10ms, TR = 400ms,
α = 90◦, bandwidth = 238 kHz, and no averaging. Twelve
0.5mm thick slices with a slice gap of 0.5mm were recorded
in axial orientation with a field-of-view = 23.7 × 23.7mm,
and a matrix of 64 × 64 to give a nominal resolution of
370 × 219µm. A series of 300 images with a temporal
resolution of 400ms were acquired. Animals were injected
intravenously with a bolus of SPIOs (30mg Fe/kg body
weight, Endorem, Guerbet) with an infusion pump at a
constant flow of 2ml/min (Harvard apparatus) after 30 s of
recorded baseline. The total procedures lasted about 2.5–3 h per
animal.
Data Processing
From the dynamic GE EPI sequence, rCBV(DSC), and rCBF
maps were generated by voxel-wise fitting the DSC-MRI data
using custom-written MATLAB code (The MathWorks, Natick,
MA) based on a previously described algorithm (Kim et al., 2010).
Signal-time curves were converted to the transverse relaxation
rate change which reflects concentration-time relationship with
the following equation (Østergaard, 2005):
Ct(t) ∝ 1R2(t) = −
k
TE
ln
(
S(t)
S0
)
(1)
where Ct(t) is the contrast agent concentration in tissue at time
t, 1R2(t) is the relaxation rate of the voxel at time t; S(t) is the
signal intensity of the voxel at time t, S0 is the precontrast signal
intensity, k is the proportionality factor, and TE is the echo time
(ms).
After brain masking, the contrast bolus arrival time was
estimated using a linear-quadratic piecewise continuous
regression model (Cheong et al., 2003). A gamma-variate curve
was then fitted to the relevant part [from bolus arrival time to
bolus arrival time + 2.5 × (bolus arrival time-time to peak)]
of the concentration-time curve by a least squares fit (Madsen,
1992). The arterial input function was estimated from a search
algorithm using an artery-likelihood metric. The rCBV(DSC)
was then computed as the integral of the fitted gamma-variate
curve, normalized over the integral of the arterial input
function:
rCBV =
∞∫
−∞
Ct(τ)dτ
∞∫
−∞
Ca(τ)dτ
(2)
rCBFwas estimated by deconvolving themeasured concentration
time curve Ct(τ) with the change in the feeding artery Ca(t).
Deconvolution was achieved using singular value decomposition
with a truncation parameter rtrunc = 0.2.
From the pre- and postcontrast SE and GE images the
transverse relaxation rates were computed according to:
1R2 =
1
TE
ln(
Spre
Spost
) (3)
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1R∗2 =
1
TE
ln(
S∗pre)
S∗post)
(4)
where Spre and Spost represent the precontrast and postcontrast
signal intensities for the SE images and S∗pre and S
∗
post the
precontrast and postcontrast signal intensities for the GE images,
and TE is the echo time.
Maps of the relaxation shift index Q where computed voxel-
wise according to Wu et al. (2004b):
Q ≡
1R2
(1R∗2)
2/3
(5)
The 1R∗2 images were resampled on the grid of the 1R2 images
using cubic spline interpolation to achieve the same spatial
resolution. And all negative values for 1R2 and 1R
∗
2 were set
to zero to avoid complex values. Microvessel density N was
calculated according to Wu et al. (2004b):
N ≈ Q3 × 329 s/mm2 (6)
For a steady-state blood tracer concentration to the total amount
of tracer in the voxel is proportional to local rCBV and thus1R∗2
yields estimation of rCBV (Berry et al., 1996). We have denoted
this as rCBV(1R∗2).
One 13-month old arcAβ mouse was excluded from the
analysis because of movements between pre and post-contrast
agent scan.
Data Analysis
Regions-of-interest (ROIs) were drawnmanually on coronal pre-
contrast 2D SE images by a person blinded to the experimental
groups and then transferred onto Q and1R∗2 maps. The olfactory
bulb, cerebral cortex, striatum, hippocampus, thalamus, and
cerebellum were identified according to an anatomical mouse
brain atlas (Franklin and Paxinos, 1997). In addition, ROIs over
the cerebral cortex, hippocampus, and cerebellum were drawn
manually on the TrueFISP images and transferred onto rCBF and
rCBV(DSC) maps using MATLAB based software Aedes (http://
aedes.uef.fi).
Immunohistology
After MRI measurements mice were decapitated and brains
were removed and snap frozen in 2-methylbutane (Sigma-
Aldrich), precooled to −60◦C. Brains were cut into 10µm
coronal sections with a cryostat (Thermo Fisher CryoStar
NX70). After air-drying, sections were fixed in acetone at
room temperature and placed in Bond wash solution. Sections
were incubated with the primary antibodies anti-murine CD31
(Rat, 1:250, catalog#NB100-1642; Novus Biological) and anti-
β-amyloid (Mouse, 1:3000 Aβ1-16 specific, catalog#SIG 3920,
Signet Covance) for 45min in a humid chamber. After two
washing steps in Bond wash solution for 5min each, sections
were incubated for 45min at room temperature in humid
chamber with secondary antibodies: anti-rat DyLight 549
(Donkey, 1:200, catalog#712-506-153, Jackson Immunoresearch)
FIGURE 1 | Representative axial images of a mouse brain at different anatomical locations. Images were acquired with a TrueFISP sequence (A) before
injection of SPIOs. Corresponding rCBV(DSC) (B) and rCBF (C) maps obtained from the dynamic GE EPI sequence. Region-of-interests were drawn over the cerebral
cortex (CC), hippocampus (HC), and cerebellum (CB) as indicated.
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FIGURE 2 | Box plots of rCBV(DSC) (A,B) and rCBF (C,D) from DSC-MRI. Values were measured in the cerebral cortex (CC), hippocampus (HC), and cerebellum
(CB) in 13-months (A,C) and 24-months (B,D) old arcAβ mice and non-transgenic littermates (NTL). Center lines show the medians; box limits indicate the 25th and
75th percentiles; whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles, outliers are represented by dots.
TABLE 1 | Linear mixed effect analysis of rCBV(DSC), rCBV(1R*
2
) rCBF,
and Q-values measured in different brain regions.
13-months old 24-months old
rCBV(DSC)
Cerebral cortex 0.470 0.007
Hippocampus 0.813 0.262
Cerebellum 0.086 0.106
rCBF
Cerebral cortex 0.334 0.208
Hippocampus 0.138 0.656
Cerebellum 0.282 <0.001
rCBV(1R*
2
)
Olfactory bulb 0.902 0.996
Cerebral cortex 0.890 0.002
Striatum 0.117 0.197
Hippocampus 0.684 0.078
Thalamus 0.629 0.173
Cerebellum 0.088 0.018
Q
Olfactory bulb 0.590 0.026
Cerebral cortex 0.667 0.001
Striatum 0.766 0.001
Hippocampus 0.949 0.003
Thalamus 0.911 0.397
Cerebellum 0.516 0.004
Shown are the p-values for the genotype effects for each age group. Highlighted are
statistically significant effects.
and anti-mouse DyLight 406 (Donkey, 1:200, catalog#715-475-
151, Jackson Immunoresearch). After the second incubation,
sections were washed in Bond wash solution and embedded with
aqueous medium (Medi-Mount, Medite, Germany). Sections
were scanned with a Pannoramic SCAN digital slide scanner
(3DHISTECH, Hungary). CD31 and Aβ were excited and
detected with DAPI and Alexa 568 filters (λex = BP387/11,
λem = BP 440/40 and λex = BP560/25 m, λem = BP 607/36
respectively). Vascular density was qualitatively evaluated in the
same ROIs investigated with Q mapping using random fields of
view (size = 862× 1330µm). Aβ deposits were clearly visible in
arcAβ mice as parenchymal plaques and vascular deposits with
no specific fluorescence in sections of NTLs (Figures 5, 6).
Statistical Analysis
Data are presented as box plots (http://boxplot.tyerslab.com/).
For each brain region, linear mixed effects analysis was
performed using R (https://www.r-project.org/) and lme4 (Bates
et al., 2015). Genotype and age were considered as fixed effects,
while individual animals were entered as random effects into the
model. Values of P < 0.05 were considered significant.
RESULTS
Physiological Parameters during Data
Acquisition
Since data acquisition for Q mapping requires long scan times
during which mice need to be anesthetized, we monitored animal
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FIGURE 3 | Coronal spin echo images (A) before injection of SPIOs and corresponding 1R*
2
(B) and Q maps (C) from steady-state measurements.
Illustration of region-of-interests are delineated for the olfactory bulb (OB), cerebral cortex (CC), striatum (ST), hippocampus (HC), thalamus (TH), and cerebellum (CB).
physiology over a 2 h period of isoflurane anesthesia in 24-month
old NTLs and arcAβ (Supplementary Table 1). In both groups
arterial blood pressure and blood gas values did not differ
between NTLs and arcAβ mice.
Assessing Vascular Parameters with MRI
Representative rCBV(DSC) and rCBF maps of mice brains
are depicted in Figures 1A–C. In different brain regions
rCBV(DSC) and rCBF values were measured by ROI analysis.
The corresponding box plots are depicted in Figures 2A–D.
Linear mixed effect modeling found no significant association
between rCBV(DSC) or rCBF and genotype in 13-month old
mice for any of the evaluated brain regions. In 24-month old
mice there was a significant association for rCBV(DSC) with
genotype in the cerebral cortex, while there was no association
in the hippocampus and cerebellum (Table 1). The rCBV in the
cerebral cortex was increased by 21%. In contrast, for rCBF there
was a significant association with genotype in the cerebellum of
24-month old mice, but no association in the cerebral cortex and
hippocampus. The rCBF was reduced by 35% in the cerebellum
of the arcAβ compared to non-transgenic controls.
Examples of high resolution spin echo images, rCBV(1R∗2)
and Q maps are shown in Figure 3. ROI analysis obtained values
for rCBV(1R∗2) and Q as shown in box plots in Figures 4A–D.
The vessel density N was calculated from Q-values for each
brain region (Figures 4E,F). Linear mixed effect modeling found
no significant association between 1R∗2 and genotype in 13-
month old mice for any of the evaluated brain regions. In
24-month old mice there was a significant association for
rCBV(1R∗2) with genotype in the cerebral cortex and cerebellum,
while there was no association in the other brain regions
(Table 1). The rCBV(1R∗2) in the cerebral cortex and in the
cerebellum were both increased by 25%. There was no significant
association for Q-values with genotype in 13-month old mice in
all regions tested. Q-values in the olfactory bulb, cerebral cortex,
striatum, hippocampus, and cerebellum in 24-month old mice
were significantly associated with genotype, while there was no
statistical association for the thalamus. In 24-month old arcAβ
mice Q-values were reduced by 11% in the olfactory bulb, 15% in
the cerebral cortex, 26% in the striatum, 20% in the hippocampus,
and 19% in the cerebellum compared to age-matched NTLs.
Assessment of Microvessel Density with
Vessel Staining
To reveal the density of cerebral blood vessels, coronal
cryosections were immunostained for CD31. Representative
Frontiers in Aging Neuroscience | www.frontiersin.org 6 January 2016 | Volume 7 | Article 241
Ielacqua et al. Cerebral Microvascular Density Mapping
FIGURE 4 | Box plots of the rCBV(1R*
2
) (A,B), relaxation shift index Q (C,D), and microvessel density N (E,F) in the olfactory bulb (OB), cerebral cortex
(CC), striatum (ST), hippocampus (HC), thalamus (TH), and cerebellum (CB) in 13-months (A,C,E) and 24-months (B,D,F) old arcAβ mice and
non-transgenic littermates (NTL). Center lines show the medians; box limits indicate the 25th and 75th percentiles; whiskers extend 1.5 times the interquartile
range from the 25th and 75th percentiles, outliers are represented by dots.
images of vessel stainings for the normal mouse brain of different
ages are presented in Figure 5. In the investigated brain regions,
there were no region-specific differences in immunoreactivity,
and there were no differences in vessel densities between 13-
and 24-month old NTLs. Figure 6 depicts examples of anti-
CD31 immunostaining for arcAβ mice of different ages. Vessel
densities were reduced in all brain regions examined, except
for the thalamus. Vessel density reduction was most apparent
in the cerebral cortex, and cerebellum of 24-month old arcAβ
mice compared to age-matched NTLs, while there was no
apparent difference in vessel density in the thalamus. Anti-Aβ
immunohistochemistry revealed the presence of vascular and
parenchymal Aβ deposits in all brain regions examined with
exception of the thalamus in 13- and 24-month old arcAβ mice,
with an age-dependent increase in the number of fibrillar plaques
(Figure 6). In the cerebellum of 24-month old arcAβmicemainly
vascular Aβ deposits were observed with few parenchymal Aβ
deposits. NTLs had no Aβ immunoreactivity (Figure 5).
DISCUSSION
In the present work we applied a protocol that yielded the
four MRI parameters rCBV(DSC), rCBV(1R∗2) and, rCBF and
the relaxation shift index Q, all describing function of the
cerebral vasculature, in the same animal. For this purpose
we have combined methods that use iron oxide contrast
agent administration. Moreover, the protocol enabled us to
compare directly rCBV estimates from DSC-MRI and steady-
state measurement of 1R∗2 . We investigated which of the read-
outs is most suitable to detect pathological changes of the cerebral
microvasculature induced by amyloidosis in transgenic arcAβ
mice.
Estimates of rCBV from DSC-MRI showed a smaller variance
compared to values derived from steady-state measurements of
1R∗2 . We observed no difference in rCBV estimates in 13-month
old animals. In 24-month old arcAβmice a significant increase in
rCBV(DSC) and rCBV(1R∗2) were found in the cerebral cortex.
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FIGURE 5 | Immunohistochemistry for vessel staining (CD31) and β-amyloid comparing 13- and 24-month old non-transgenic littermates. Overviews
(scale bars = 200µm) of the corpus callosum (CC), thalamus (TH), and cerebellum (CB). Insets show the regions with higher magnification (scale bar = 50µm).
Only for the cerebellum the analysis yielded differences for the
two methods as we found no differences in rCBV(DSC) but
a significant increase in rCBV(1R∗2) values. Our finding are
in contrast to previous studies which have estimated rCBV in
different APP mouse strains by measuring 1R2 or 1R
∗
2 after
injection of an iron oxide contrast agent (Wu et al., 2004a;
Weidensteiner et al., 2009). Wu et al. (2004a) found a decrease
in rCBV in the cerebral cortex, hippocampus and thalamus, in
4-month old PDAPP mice compared to non-transgenic controls.
Weidensteiner et al. (2009) reported reduced rCBV values for the
cortex and hippocampus in 17-month old B6.Ps2APP mice and a
reduction in rCBF in the occipital cortex of 10- to 17-month-old
mice compared to control.
Moreover, we additionally obtained rCBF values with the
DSC-MRI. We observed a decrease in rCBF in the cerebellum,
and no differences in the other brain regions. This is in contrast to
other studies that have assessed cerebral perfusion in transgenic
APP mice by applying arterial spin labeling techniques (Massaad
et al., 2010; Faure et al., 2011; Poisnel et al., 2012; Hébert et al.,
2013). Reductions in rCBF was found in the cortex in 6-month-
old APPxPS1-Ki (Faure et al., 2011), 12-month old APP/PS1
(Poisnel et al., 2012), 3-month-old J20 hAPP (Hébert et al.,
2013), and in 12- to 16-month-old Tg2576 mice (Massaad et al.,
2010).
With Q mapping we found average values of 0.63± 0.11 s−1/3
for gray mater regions in 13-month old NTLs. This is in good
agreement withQ-values of 0.72± 0.21 s−1/3 that were estimated
for similar regions by Jensen and Chandra (2000), but is lower
compared to Q-values of 0.95 ± 0.05 s−1/3 reported by Wu
et al. (2004b). Differences in Q-values might be attributed to
differences in mouse strains and ages, but also in the drawing
of the ROIs which might lead to the inclusions of different
proportions of larger vessels within a ROI (Wu et al., 2004a).
Weidensteiner et al. (2009) have previously applied Q mapping
to assess microvessel density in B6.Ps2APP mice. They found
no difference in vessel density in the brains of 17-month old
B6.Ps2APP mice, despite the fact that an immunohistological
study had shown a reduction in microvessel density in the
cortex in the same mouse strain and age (Kouznetsova et al.,
2006). We measured decreased microvessel density in different
brain regions in 24-month old arcAβ mice, which were
corroborated by results of vessel staining using anti-CD31
immunohistochemistry. A reduction in microvessel density was
shown to occur in brain areas that were previously shown to be
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FIGURE 6 | Immunohistochemistry for vessel staining (CD31) and β-amyloid comparing 13- and 24-month old arcAβ mice. Overviews (scale bars =
200µm) of the corpus callosum (CC), thalamus (TH), and cerebellum (CB). Insets show the regions with higher magnification (scale bar = 50µm).
predominant sites of Aβ deposition (Knobloch et al., 2007; Klohs
et al., 2013), and which was confirmed in this study using CD31
vessel staining. The decrease in microvessel density is clearly age-
dependent as there was no reduction in 13-month old arcAβ
mice.
Differences in hemodynamic read-outs might arise from the
different transgenic APP mouse strains used in the studies with
differences in onset and severity of amyloid pathology, and a
different degree of vascular involvement (Klohs et al., 2014).
However, the rCBV, and, in a more complicated relation, the
rCBF are both proportional to the fraction of vessels within
the voxel (Pathak et al., 2001), and we expected to observe a
decrease in rCBV and rCBF in areas with reduced microvessel
density. However, in most cases rCBV (both DSC and 1R∗2)
and rCBF were unchanged or even increased in 24-month
old arcAβ, indicating an unaffected or increased blood vessel
density and/or size in the brain regions. That we did not find
an association between rCBV, rCBF and microvessel density
might be likely explained by the constraints of the methods to
derive hemodynamic parameters. It has been previously shown
that Aβ pathology in the arcAβ mouse strain affects mainly
the microvasculature (Merlini et al., 2011; Klohs et al., 2012,
2015) and this goes together with the reduction in the density
of microvessels that we observed in this study. However, both
DSC-MRI and steady-state measurements of rCBV using an
intravascular iron oxide contrast agent are inherently sensitive
to all vessels within a voxel (Simonsen et al., 2000; Zerbi et al.,
2013) and it might be conceivable that focal reductions in rCBV
and rCBF might be concealed in larger voxels by larger vessels
that are not affected by disease. Compared with these methods,
Q mapping has been shown to be sensitive to the density of
the microvasculature (Jensen and Chandra, 2000) and has thus
revealed the decrease in microvessel density that we have also
found with immunohistochemistry.
With CD31 vessel staining we observed a clear decrease
in cerebral microvessel density in 24-month old arcAβ in
brain regions that also showed a reduction in Q and N.
The decreased immunoreactivity in these brains suggests that
there is an extensive loss of endothelial cells in the advanced
disease stage. The present findings are highly consistent with
numerous neuropathological reports describing a degeneration
of microvessels in certain brain regions in AD patients (Bell and
Ball, 1986; Fischer et al., 1990; Buèe et al., 1997; Bouras et al.,
2006) and APP mice (Lee et al., 2005; Kouznetsova et al., 2006).
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Differences exist with respect to the cerebellum where we found
a decreased microvessel density in the arcAβ mouse. Previous
studies (Knobloch et al., 2007; Klohs et al., 2013) and histological
analysis have shown that the cerebellum in this strain is affected
by, though mainly vascular, Aβ deposition.
Many studies have described the pathogenic effect of Aβ
on the vasculature. For example, neuropathological studies
demonstrated that Aβ is associated with structural changes in the
vessels including loss of smooth muscle cells, fibrinoid necrosis,
and weakening of the vessel wall (Greenberg et al., 1995) as
well as apoptosis (Miao et al., 2005). In vitro studies have
demonstrated that fibrillar Aβ, but not soluble Aβ oligomers,
promotes cell degeneration and apoptosis in primary cultures
of cerebrovascular smooth muscle cells and pericytes (Van
Nostrand et al., 1997; Verbeek et al., 1997; Davis et al., 1999).
Additionally, in culture Aβ has been shown to be toxic to
endothelial cells (Thomas et al., 1996; Price et al., 2001). This is
in line with our finding that the thalamus which was devoid of
Aβ deposits had a normal vessel density. However, there were no
correlation between the extent of Aβ deposits and the decrease in
microvessel density as the striatum which has shown the largest
decrease in Q has a rather low number of Aβ deposits compared
to the cerebral cortex which has a high Aβ load but a smaller
reduction in Q. Moreover, a reduction of microvessel density
was observed in the cerebellum where mainly vascular Aβ was
observed, indicating that parenchymal Aβ is not required for the
degeneration of the microvessels.
To date, the interaction between pathological alterations of
the cerebral microvasculature, changes in hemodynamic and
cognitive function in AD pathogenesis is not well understood.
Using neuroimaging cerebral hypoperfusion has been shown to
occur in AD patients and already in patients with mild cognitive
impairment (Hirao et al., 2005; Johnson et al., 2005). Histological
studies have revealed a reduction in microvessel density in AD
patients with dementia (Bell and Ball, 1986; Fischer et al., 1990;
Buèe et al., 1997; Bouras et al., 2006). As such studies rely on
the examination of postmortem samples that are become largely
available during the late stage of the disease it remains unclear
at which stage the microvasculature starts to degenerate and
how this is related to changes in hemodynamics. Moreover, it
is conceivable that a reduction in microvessel density will affect
tissue viability, but future studies are warranted to assess the
relationship between the extent of microvascular degeneration
and the degree of cognitive impairment. The application of Q
mapping to patients with brain tumor (Donahue et al., 2000;
Schmainda et al., 2004) and cerebral ischemia (Xu et al., 2011,
2012) has been already demonstrated. Previous reports have
shown a good correlation between histological and Q mapping
measures of microvessel density (Ullrich et al., 2011; Lemasson
et al., 2013). In this study we have foundQmappingmore suitable
than the assessment of hemodynamic parameters, suggesting
that Q mapping could be employed to non-invasively and
quantitatively assess degeneration of the microvasculature in
AD patients. Assessing microvessel density could thus provide
a useful tool for the characterization and clinical staging of
vascular dysfunction in patients with AD and cerebrovascular
diseases.
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